Skip to main content
SpringerLink
Log in

CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells

  • Original Article
  • Published:
Tumor Biology

Abstract

Dysregulation of Hippo-Yes-associate protein (YAP) signaling has important roles in the tumorigenesis of hepatocellular carcinoma (HCC). Our previous studies have shown that Cip1 interacting zinc finger protein 1 (CIZ1) activated YAP signaling in the HCC cells and promoted the growth and migration of cancer cells. However, the mechanisms for the activation of YAP signaling by CIZ1 are unknown. In this study, it was found that CIZ1 interacted with the transcriptional factor YAP in HCC cells. The nuclear matrix anchor domain of CIZ1 is responsible for its interaction with YAP. Moreover, CIZ1 enhanced the interaction between YAP and TEAD. Knocking down the expression of CIZ1 impaired the transcriptional activity as well as the biological functions of YAP. Taken together, our study demonstrated that CIZ1 is a positive regulator of YAP signaling, and CIZ1 might be a therapeutic target for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Badouel C, McNeill H. SnapShot: the Hippo signaling pathway. Cell. 2011;145(3):484–484 e1.

    Article  CAS  PubMed  Google Scholar 

  3. Zhao B, Guan KL. Hippo pathway key to ploidy checkpoint. Cell. 2014;158(4):695–6.

    Article  CAS  PubMed  Google Scholar 

  4. Zhang W et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhang K et al. YAP and TAZ take center stage in cancer. Biochemistry. 2015;54(43):6555–66.

    Article  CAS  PubMed  Google Scholar 

  6. Avril T, Chevet E. Proteostasis trumps YAP in colon cancer. Sci Signal. 2015;8(397):fs18.

    Article  PubMed  Google Scholar 

  7. Yang S et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 2015;6(34):36019–31.

    PubMed  PubMed Central  Google Scholar 

  8. Zhao B, Lei Q, Guan KL. Mst out and HCC in. Cancer Cell. 2009;16(5):363–4.

    Article  CAS  PubMed  Google Scholar 

  9. Jie L et al. The Hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract. 2013;2013:187070.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wang C et al. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells. Mol Med Rep. 2015;11(6):4101–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Perra A et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–96.

    Article  CAS  PubMed  Google Scholar 

  12. Han SX et al. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res. 2014;2014:261365.

    PubMed  PubMed Central  Google Scholar 

  13. Li H et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 2014;31(6):468–78.

    Article  CAS  PubMed  Google Scholar 

  14. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394(3):623–7.

    Article  CAS  PubMed  Google Scholar 

  15. Wang Y et al. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR. Acta Pharmacol Sin. 2014;35(9):1207–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Higashi T et al. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells. Br J Cancer. 2015;113(2):252–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Li X et al. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6(12):10102–15.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Li L et al. MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 2013;587(24):3921–7.

    Article  CAS  PubMed  Google Scholar 

  19. Xu MZ et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 2011;30(10):1229–40.

    Article  CAS  PubMed  Google Scholar 

  20. Copeland NA et al. Cyclin-A-CDK2-mediated phosphorylation of CIZ1 blocks replisome formation and initiation of mammalian DNA replication. J Cell Sci. 2015;128(8):1518–27.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang D et al. CIZ1 promoted the growth and migration of gallbladder cancer cells. Tumour Biol. 2015;36(4):2583–91.

    Article  CAS  PubMed  Google Scholar 

  22. Warder DE, Keherly MJ. Ciz1, Cip1 interacting zinc finger protein 1 binds the consensus DNA sequence ARYSR(0–2)YYAC. J Biomed Sci. 2003;10(4):406–17.

    CAS  PubMed  Google Scholar 

  23. Higgins G et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci U S A. 2012;109(45):E3128–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets. 2008;9(11):1013–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by International Science and Technology Cooperation Program of the Ministry of Science and Technology (2011DFA32980), One Hundred Person Project of the Shanghai Health (XBR2013117), and the National Natural Science Foundation of China (NSFC81271694).

Author information

Authors and Affiliations

  1. Department of Hepatobiliary & Pancreatic Surgery, Huai’an First People’s Hospital, Nanjing Medical University, 6th of West Beijing Road, Huai’an, Jiangsu Province, 223300, China

    Liu Lei, Jinsheng Wu, Dianhua Gu & Shaochuang Wang

  2. Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai, 200438, China

    Hui Liu

Authors
  1. Liu Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinsheng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dianhua Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaochuang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hui Liu or Shaochuang Wang.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lei, L., Wu, J., Gu, D. et al. CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells. Tumor Biol. 37, 11073–11079 (2016). https://doi.org/10.1007/s13277-016-4866-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-4866-8

Keywords

Search

Navigation